Therefore, engineering NDV to express tumour-specific and/or tissue-specific gene promoters, such as high molecular weight mucin-like glycoprotein, DF3 (MUC1), prostate-specific antigen (PSA) and alpha fetoprotein (AFP), can optimize the targeting effect of NDV and limit virus replication to specific tumour cells. The gene discussed is PROS1; the disease is neoplasm.